Literature DB >> 16344384

Peristent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study.

Jiro Aoki1, Antonio Colombo, Dariusz Dudek, Adrian P Banning, Janusz Drzewiecki, Krzysztof Zmudka, Francois Schiele, Mary E Russell, Joerg Koglin, Patrick W Serruys.   

Abstract

BACKGROUND: The purpose of this study was to evaluate long-term vascular responses as long as 2 years after implantation of polymer-based, paclitaxel-eluting stents in contrast to uncoated stents. METHODS AND
RESULTS: TAXUS II is a randomized, double-blind trial comparing slow-release (SR) and moderate-release (MR) TAXUS stents with bare-metal control stents (BMSs). One hundred sixty-one event-free patients (SR, 43; MR, 41; and BMS, 77) underwent serial intravascular ultrasound (IVUS) analysis after the procedure and at 6 months and 2 years. At 2 years, neointimal responses continued to be significantly suppressed in the SR and MR groups when compared with the BMS group (BMS, 1.49+/-1.12 mm2; SR, 0.94+/-0.76 mm2 [P=0.004]; and MR, 1.06+/-0.90 mm2 [P=0.02]). Between 6 months and 2 years, the BMS group showed compaction of the neointima (Delta, -0.22+/-1.05 mm2 [P=0.08]). In contrast, both the SR and MR groups exhibited an increase (Delta SR, 0.30+/-0.76 mm2 (P=0.01); MR, 0.41+/-0.94 mm2 [P=0.009]). Between 6 months and 2 years, the initial increase in plaque outside the stent regressed in the BMS and SR groups to levels comparable to those after the procedure, whereas expansive remodeling partially regressed in the MR group (Delta between after the procedure and 2 years BMS, -0.34+/-1.28 mm2 [P=0.05]; SR, -0.02+/-1.40 mm2 [P=0.93]; MR, 0.32+/-1.56 mm2 [P=0.27]).
CONCLUSIONS: The 2-year follow-up demonstrates that neointimal suppression was dose independent and that this effect was still sustained at 2 years. However, the increase in area outside the stent seen at 6 months regressed to different extents in a dose-dependent manner at 2 years.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16344384     DOI: 10.1161/CIRCULATIONAHA.105.558601

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

1.  Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold.

Authors:  Salvatore Brugaletta; Hector M Garcia-Garcia; Scot Garg; Josep Gomez-Lara; Roberto Diletti; Yoshinobu Onuma; Robert Jan van Geuns; Dougal McClean; Dariusz Dudek; Leif Thuesen; Bernard Chevalier; Stephan Windecker; Robert Whitbourn; Cecile Dorange; Karine Miquel-Hebert; Krishnankutty Sudhir; John A Ormiston; Patrick W Serruys
Journal:  Int J Cardiovasc Imaging       Date:  2010-10-13       Impact factor: 2.357

2.  Comparison of intravascular ultrasonic imaging with versus without incomplete stent apposition at follow-up after drug-eluting stent implantation.

Authors:  Juying Qian; Feng Zhang; Hongyi Wu; Bing Fan; Lei Ge; Junbo Ge
Journal:  Int J Cardiovasc Imaging       Date:  2007-08-17       Impact factor: 2.357

3.  The paclitaxel-eluting Coroflex Please stent pilot study (PECOPS I) : the one-year clinical follow-up.

Authors:  Martin Unverdorben; Ralf Degenhardt; Marcus Wiemer; Dieter Horstkotte; Henrik Schneider; Christoph Nienaber; Wolfgang Bocksch; Michael Gross; Michael Boxberger; Christian Vallbracht
Journal:  Clin Res Cardiol       Date:  2007-08-23       Impact factor: 5.460

Review 4.  Assessment of drug-eluting stents and bioresorbable stents by grayscale IVUS and IVUS-based imaging modalities.

Authors:  Salvatore Brugaletta; Jose Ribamar Costa; Hector M Garcia-Garcia
Journal:  Int J Cardiovasc Imaging       Date:  2011-01-30       Impact factor: 2.357

Review 5.  Is late stent thrombosis in drug-eluting stents a real clinical issue? A single-center experience and review of the literature.

Authors:  J Carlsson; B von Wagenheim; R Linder; T M Anwari; J Qvist; I Petersson; T Magounakis; B Lagerqvist
Journal:  Clin Res Cardiol       Date:  2006-12-22       Impact factor: 5.460

6.  Serial angiographic and intravascular ultrasound evaluation to interrogate the presence of late "catch-up" phenomenon after Cypher® sirolimus-eluting stent implantation.

Authors:  Daniel Chamié; Alexandre Abizaid; J Ribamar Costa; Fausto Feres; J Fábio Almiro da Silva; Luiz Alberto P Mattos; Rodolfo Staico; Ricardo A Costa; Andréa Abizaid; Luiz Fernando L Tanajura; Amanda G M R Sousa; J Eduardo Sousa
Journal:  Int J Cardiovasc Imaging       Date:  2010-11-17       Impact factor: 2.357

7.  Serial angioscopic evaluation of neointimal coverage and incidence of thrombus formation after Paclitaxel-eluting stent implantation: comparison between 6- and 18-month follow-up.

Authors:  Masahiko Hara; Masami Nishino; Masayuki Taniike; Nobuhiko Makino; Hiroyasu Kato; Yasuyuki Egami; Ryu Shutta; Jun Tanouchi; Yoshio Yamada
Journal:  Clin Cardiol       Date:  2011-03-22       Impact factor: 2.882

8.  Temporal course of neointimal hyperplasia following drug-eluting stent implantation: a serial follow-up optical coherence tomography analysis.

Authors:  Seung-Yul Lee; Myeong-Ki Hong; Gary S Mintz; Dong-Ho Shin; Jung-Sun Kim; Byeong-Keuk Kim; Young-Guk Ko; Donghoon Choi; Yangsoo Jang
Journal:  Int J Cardiovasc Imaging       Date:  2014-05-08       Impact factor: 2.357

9.  Quantitative multi-modality imaging analysis of a fully bioresorbable stent: a head-to-head comparison between QCA, IVUS and OCT.

Authors:  Juan Luis Gutiérrez-Chico; Patrick W Serruys; Chrysafios Girasis; Scot Garg; Yoshinobu Onuma; Salvatore Brugaletta; Héctor García-García; Gerrit-Anne van Es; Evelyn Regar
Journal:  Int J Cardiovasc Imaging       Date:  2011-02-26       Impact factor: 2.357

Review 10.  Estrogen-eluting stents.

Authors:  Sung Kee Ryu; Ehtisham Mahmud; Sotirios Tsimikas
Journal:  J Cardiovasc Transl Res       Date:  2009-05-19       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.